India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
India’s pharmaceutical sector stands at a pivotal inflection point
The state-of-the-art laboratory opens at the Corewell Health Southfield Center in early 2027
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
Subscribe To Our Newsletter & Stay Updated
